Vedolizumab study for ulcerative colitis and gut changes
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years old or older and have moderate-to-severe ulcerative colitis
- You have a doctor’s recommendation to start vedolizumab
- You have never taken vedolizumab before
- You have not used biologic medicines before, or you stopped them more than 12 weeks ago
- You have not taken antibiotics or probiotics in the last 4 weeks
- You can fully take part in the study on your own and agree to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This study tests whether adding a special probiotic (VSL#3) to vedolizumab helps people with moderate ulcerative colitis more than vedolizumab alone. You may qualify if you are already planning to start vedolizumab and haven't responded well enough to other treatments.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This study tests whether adding a herbal supplement called CurQD to the standard treatment vedolizumab can help control ulcerative colitis symptoms better than vedolizumab alone. It aims to see if the combination reduces inflammation and improves quality of life for people with active disease.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.